Lanthanum carbonate for dialysis patients with hyperphosphataemia resistant to sevelamer: A retrospective cohort study

References

• Al-Baaj, F., Speake, M., & Hutchison, A. J. (2005). Control of serum phosphate by oral lanthanum carbonate in patients undergoing haemodialysis and continuous ambulatory peritoneal dialysis in a short-term, placebo-controlled study. Nephrology Dialysis Transplantation, 20, 775–782. doi:10.1093/ndt/gfh693
   Google Scholar
• Arenas, M. D., Rebollo, P., Malek, T., Moledous, A., Gil, M. T., Alvarez-Ude, F., … Cotilla, E. (2010). A comparative study of 2 new phosphate binders (sevelamer and lanthanum carbonate) in routine clinical practice. Journal of Nephrology, 23, 683–692.
   Google Scholar
• Block, G. A., Hulbert-Shearon, T. E., Levin, N. W., & Port, F. K. (1998). Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. American Journal of Kidney Diseases, 31, 607–617.10.1053/ajkd.1998.v31.pm9531176
   Google Scholar
• Block, G. A., Klassen, P. S., Lazarus, J. M., Ofsthun, N., Lowrie, E. G., & Chertow, G. M. (2004). Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. Journal of the American Society of Nephrology, 15, 2208–2218. doi:10.1097/01.ASN.0000133041.27682.A2
   Google Scholar
• Filiopoulos, V., Koutis, I., Trompouki, S., Hadjiyannakos, D., Lazarou, D., & Vlassopoulos, D. (2011). Lanthanum carbonate versus sevelamer hydrochloride: Improvement of metabolic acidosis and hyperkalemia in hemodialysis patients. Therapeutic Apheresis and Dialysis, 15, 20–27. doi:10.1111/j.1744-9987.2010.00868.x
   Google Scholar
• Ganesh, S. K., Stack, A. G., Levin, N. W., Hulbert-Shearon, T., & Port, F. K. (2001). Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. Journal of the American Society of Nephrology, 12, 2131–2138.
   Google Scholar
• Hutchison, A. J. (2009). Oral phosphate binders. Kidney International, 75, 906–914. doi:10.1038/ki.2009.60
   Google Scholar
• Hutchison, A. J., Speake, M., & Al-Baaj, F. (2004). Reducing high phosphate levels in patients with chronic renal failure undergoing dialysis: A 4-week, dose-finding, open-label study with lanthanum carbonate. Nephrology Dialysis Transplantation, 19, 1902–1906. doi:10.1093/ndt/gfh282
   Google Scholar
• Isakova, T., Gutierrez, O. M., Chang, Y., Shah, A., Tamez, H., Smith, K., … Wolf, M. (2009). Phosphorus binders and survival on hemodialysis. Journal of the American Society of Nephrology, 20, 388–396. doi:10.1681/ASN.2008060609
   Google Scholar
• Jamal, S. A., Fitchett, D., Lok, C. E., Mendelssohn, D. C., & Tsuyuki, R. T. (2009). The effects of calcium-based versus non-calcium-based phosphate binders on mortality among patients with chronic kidney disease: A meta-analysis. Nephrology Dialysis Transplantation, 24, 3168–3174. doi:10.1093/ndt/gfp350
   Google Scholar
• Joy, M. S., Finn, W. F., & Group LAMS (2003). Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: A new phosphate binder for the treatment of hyperphosphatemia. American Journal of Kidney Diseases, 42, 96–107.10.1016/S0272-6386(03)00554-7
   Google Scholar
• Kasai, S., Sato, K., Murata, Y., & Kinoshita, Y. (2012). Randomized crossover study of the efficacy and safety of sevelamer hydrochloride and lanthanum carbonate in japanese patients undergoing hemodialysis. Therapeutic Apheresis and Dialysis, 16, 341–349. doi:10.1111/j.1744-9987.2012.01071.x
   Google Scholar
• Kestenbaum, B., Sampson, J. N., Rudser, K. D., Patterson, D. J., Seliger, S. L., Young, B., … Andress, D. L. (2005). Serum phosphate levels and mortality risk among people with chronic kidney disease. Journal of the American Society of Nephrology, 16, 520–528. doi:10.1681/ASN.2004070602
   Google Scholar
• Kidney Disease: Improving Global Outcomes CKDMBDWG. (2009). KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney international. Supplement, 113, 1–130. doi:10.1038/ki.2009.188
   Google Scholar
• Melamed, M. L., Eustace, J. A., Plantinga, L., Jaar, B. G., Fink, N. E., Coresh, J., … Powe, N. R. (2006). Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: A longitudinal study. Kidney International, 70, 351–357. doi:10.1038/sj.ki.5001542
   Google Scholar
• Navaneethan, S. D., Palmer, S. C., Craig, J. C., Elder, G. J., & Strippoli, G. F. (2009). Benefits and harms of phosphate binders in CKD: A systematic review of randomized controlled trials. American Journal of Kidney Diseases, 54, 619–637. doi:10.1053/j.ajkd.2009.06.004
   Google Scholar
• Salusky, I. B. (2006). A new era in phosphate binder therapy: What are the options? Kidney International, 70, 10–15. doi:10.1038/sj.ki.5001997
   Google Scholar
• Shigematsu, T., & Lanthanum Carbonate G. (2008a). Multicenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia. Clinical Nephrology, 70, 404–410.10.5414/CNP70404
   Google Scholar
• Shigematsu, T., & Lanthanum Carbonate Research G. (2008b). Lanthanum carbonate effectively controls serum phosphate without affecting serum calcium levels in patients undergoing hemodialysis. Therapeutic Apheresis and Dialysis, 12, 55–61. doi:10.1111/j.1744-9987.2007.00541.x
   Google Scholar
• Sprague, S. M., Ross, E. A., Nath, S. D., Zhang, P., Pratt, R. D., & Krause, R. (2009). Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: A crossover study. Clinical Nephrology, 72, 252–258.10.5414/CNP72252
   Google Scholar
• Suzuki, D., Ichie, T., Hayashi, H., Sugiura, Y., & Sugiyama, T. (2015). Gastrointestinal symptoms after the substitution of sevelamer hydrochloride with lanthanum carbonate in Japanese patients undergoing hemodialysis. Pharmazie, 70, 522–526.
   Google Scholar
• Tentori, F., Blayney, M. J., Albert, J. M., Gillespie, B. W., Kerr, P. G., Bommer, J., … Port, F. K. (2008). Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: The dialysis outcomes and practice patterns study (DOPPS). American Journal of Kidney Diseases, 52, 519–530. doi:10.1053/j.ajkd.2008.03.020
   Google Scholar
• Tomasello, S., Dhupar, S., & Sherman, R. A. (2004). Phosphate binders, K/DOQI guidelines, and compliance: The unfortunate reality. Dialysis & Transplantation, 33, 236–240.
   Google Scholar
• Tonelli, M., Pannu, N., & Manns, B. (2010). Oral phosphate binders in patients with kidney failure. New England Journal of Medicine, 362, 1312–1324. doi:10.1056/NEJMra0912522
   Google Scholar
• Winnie Chan, W. L., Rounsley, K., Chapman, E., Collings, K., Dale, C., De Waal, S., … Borrows, R. (2010). Lanthanum carbonate is an effective hypophosphatemic agent for hemodialysis patients intolerant of other phosphate binders. Journal of Renal Nutrition, 20, 270–277. doi:10.1053/j.jrn.2009.10.009
   Google Scholar
• Young, E. W., Akiba, T., Albert, J. M., McCarthy, J. T., Kerr, P. G., Mendelssohn, D. C., & Jadoul, M. (2004). Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). American Journal of Kidney Diseases, 44, 34–38.10.1016/S0272-6386(04)01103-5
   Google Scholar